Please ensure Javascript is enabled for purposes of website accessibility

Why bluebird bio Stock Is Flying Higher Today

By Keith Speights - Mar 10, 2021 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced good news for its beleaguered gene therapy program.

What happened

Shares of bluebird bio (BLUE -2.14%) were flying 8.2% higher as of 10:49 a.m. on Wednesday. The gain came after the biotech announced its analyses have determined it's "very unlikely" that a serious adverse reaction observed with its phase 1/2 study of LentiGlobin in treating sickle cell disease was related to the BB305 lentiviral vector (LVV) used to deliver the gene therapy.

So what

Bluebird's findings could be critical in getting its LentiGlobin program back on track. In February, the company temporarily suspended its phase 1/2 and phase 3 studies of the gene therapy in treating sickle cell disease after a patient was diagnosed with acute myeloid leukemia (AML). 

Scientist looking through a microscope

Image source: Getty Images.

The U.S. Food and Drug Administration (FDA) followed up by placing both of those studies on clinical hold. In addition, the agency placed two clinical studies of betibeglogene autotemcel in treating beta-thalassemia on clinical hold because it uses the same lentiviral vector as LentiGlobin. Bluebird temporarily suspended marketing of the gene therapy in Europe, where it's sold under the brand name Zynteglo.

Now what

Bluebird chief scientific officer Philip Gregory said the company has shared its analyses with the FDA. The company thinks the data are compelling enough to support the lifting of the FDA's clinical holds on its studies of LentiGlobin and betibeglogene autotemcel. This could be the best news for the biotech stock in a long time: Bluebird's shares have plunged nearly 50% over the last 12 months.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
BLUE
$3.20 (-2.14%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.